

SENATE RESOLUTION NO. 684

WHEREAS, Cancer remains one of the most pressing public health concerns in the United States, and it is estimated that in 2019, more than 1.7 million Americans will be diagnosed with cancer and over 600,000 will die from the disease; and

WHEREAS, One in every two men and one in every three women in the United States will learn that they have cancer during his or her lifetime; cancer is currently the second leading cause of death in the nation, and it is on track to become the number one disease-related killer; among some racial and ethnic minorities, as well as low-income and elderly populations, it exacts an even greater toll in terms of incidence, prevalence, and mortality; and

WHEREAS, Cancer is projected to cost the United States approximately \$170 billion in 2019, and the economic burden of the disease is expected to rise along with the number of cancer-related deaths; and

WHEREAS, Advancements in understanding the causes, mechanisms, diagnoses, treatment, and prevention of cancer have led to cures for many types and have converted others into manageable chronic conditions; effective therapies and screening tools for certain forms of cancer remain elusive, however, and some, such as pancreatic, liver, lung, ovarian, and brain cancer, continue to have extraordinarily high mortality rates; and

WHEREAS, Partnerships among research scientists, cancer survivors, patient advocates, philanthropic organizations, government entities, and the general public have resulted in breakthroughs that have increased early detection and survival rates and improved the quality of life of cancer sufferers; and

WHEREAS, The Cancer Prevention Research Institute of Texas is the second-largest source of cancer research after the National Cancer Institute; since its establishment in 2007, CPRIT has recruited over 170 researchers to the state, created more than 10,000 permanent jobs, increased biotech investment in the state by 11 percent, and detected over 15,000 cancer precursors and 3,500 cancers; CPRIT has additionally facilitated 109 clinical trials and studies that have involved some 13,000 patients, and the \$2 billion that the State of Texas has invested through CPRIT to date has produced \$2.7 billion in outside investment; and

WHEREAS, The State of Texas is fortunate to have scientists and researchers of exceptional skill who are on the front lines of the fight against cancer, and National Cancer Research Month in May provides an opportune time to express our support for their lifesaving efforts; now, therefore, be it

S.R. No. 684

RESOLVED, That the Senate of the State of Texas, 86th Legislature, hereby recognize May 2019 as Cancer Research Month in Texas and honor the invaluable contributions of researchers in the Lone Star State and beyond for their dedication to ending the cancer epidemic.

Watson, Huffman,
Nelson

President of the Senate

I hereby certify that the
above Resolution was adopted by
the Senate on May 2, 2019.

Secretary of the Senate

Member, Texas Senate

Member, Texas Senate

Member, Texas Senate